CoChat

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

Open access
Niessner, Alexander, Tamargo, Juan, Morais, João, Koller, Lorenz, Wassmann, Sven, Husted, Steen Elkjær, Torp-Pedersen, Christian, Kjeldsen, Keld, Lewis, Basil S., Drexel, Heinz, Kaski, Juan Carlos, Atar, Dan, Storey, Robert F., Lip, Gregory Y. H., Verheugt, Freek W. A., Agewall, Stefan · 2015 · European Heart Journal
Cited by 59

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Bleeding is the main adverse effect when using oral anticoagulants (OACs). The risk of major bleeding with vitamin K antagonists (VKAs) is dependent on the quality of anticoagulation control and estimated to be ∼1.3/100 patients/year in patients with INR 2.0–3.0.1,2 Multiple limitations of VKAs stimulated the development of non-vitamin K antagonist oral anticoagulants (NOACs) acting directly on coagulation factors, including factor FIIa (thrombin) and FXa. Pharmacological properties of the NOACs relevant for bleeding are summarized in the supplement including Supplementary material online, Table S1 and their main effects are summarized in Supplementary material online, Table S2. The risk of bleeding in patients managed with NOACs was properly assessed in the four landmark Phase III trials in patients with atrial fibrillation (AF; Table 1). Major bleeding was the principal safety outcome in RE-LY,3,4 ARISTOTLE,5 and ENGAGE AF.6 In ROCKET-AF, the primary safety endpoint was the composite of major and non-major clinically relevant bleeding.7 The risk of major bleeding was significantly reduced with dabigatran 110 mg b.i.d., apixaban and both doses of edoxaban3–6 while the bleeding rates for dabigatran 150 mg b.i.d. and rivaroxaban were similar to those with warfarin (Table 1). Risk of bleeding with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (rates per 100 patients-years) These data derive from separate studies comparing each NOAC to VKA; there are no head-to-head studies between NOACs. b.i.d., twice daily; o.d., once daily; GI, gastrointestinal; ICH, intracranial haemorrhage; NA, not applicable; NMCR, non-major clinically relevant. Risk of bleeding with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (rates per 100 patients-years) These data derive from separate studies comparing each NOAC to VKA; there are no head-to-head studies between NOACs. b.i.d., twice daily; o.d., once daily; GI, gastrointestinal; ICH, intracranial haemorrhage; NA, not applicable; NMCR, non-major clinically relevant. Gastrointestinal (GI) bleeding accounts for ∼90% of major extracranial haemorrhages in patients with AF receiving VKAs.8 With the NOACs, dabigatran 150 mg b.i.d., rivaroxaban, and edoxaban 60 mg o.d. significantly increased rates of GI bleeding (∼1.5-fold) compared with warfarin.3,6,7 While rivaroxaban increases upper and lower GI bleeding to a similar extent, dabigatran 150 mg b.i.d. prominently increased lower GI bleeding.9 Apixaban was associated with GI bleeding rates comparable with those with warfarin.5 Edoxaban 30 mg o.d. demonstrated significantly lower rates of GI bleeding compared with warfarin (Table 1).6 Intracranial haemorrhage (ICH) is the major concern in patients on OACs and this is the field where NOACs demonstrated major clinical improvement (Table 1). In the four trials, the hazard ratio for ICH was between 0.31 and 0.64, with meta-analysis showing a hazard ratio of 0.48 overall.10 Furthermore, the sequelae of ICH may be less severe when it has occurred during NOAC treatment.11 Major bleeding and ICH rates in ‘real-world’ post-marketing data for NOACs also seems to be generally reassuring, although GI bleeding rates appear to be higher for dabigatran (150 mg b.i.d.) compared with warfarin.12–14 While this paper focuses on the reversal of the effects of NOACs due to an emergency situation, prevention of bleeding remains of utmost importance. The risk of bleeding may be estimated using the well-validated HAS-BLED score.15 A high HAS-BLED score is there to ‘flag up’ patients at higher risk of bleeding for more careful review and follow-up, as well as attention to the potentially reversible risk factors for bleeding, such as uncontrolled hypertension (systolic blood pressure >160 mmHg), labile INRs (for VKA user), concomitant use of aspirin/NSAIDs, alcohol excess. Among AF patients, the HAS-BLED score has been validated to be predictive of bleeding with VKAs, aspirin, and NOACs.16–19 The need to reverse the effect of NOACs occurs in case of life-threatening bleeding, bleeding which cannot be controlled by withdrawal of OAC and usual care, or medical emergencies other than bleeding requiring immediate surgery (Figure 1). Intracranial haemorrhage, with the highest likelihood for fatal outcome, is one of the primary aims for reversal agents. A timely administration of reversal agents is likely to be of major relevance for an improved clinical outcome in case of ICH. However, bleeding at other sites may also be life-threatening and risk stratification is more difficult but essential for these bleeding events. A subanalysis of the RE-LY trial showed that attempts to reverse the effect of dabigatran with clotting factor concentrates (CFCs) were observed in <2% of all major bleeding events.20 Despite the lack of a specific reversal agent, patients in the NOAC arm showed a trend for reduced mortality associated with major bleeding compared with

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv676

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 59

Metadata

Authors
Niessner, A., Tamargo, J., Morais, J., Koller, L., Wassmann, S., Husted, S. E., Torp-Pedersen, C., Kjeldsen, K., Lewis, B. S., Drexel, H., Kaski, J. C., Atar, D., Storey, R. F., Lip, G. Y. H., Verheugt, F. W. A., & Agewall, S.
Venue
European Heart Journal
Published
2015-12-24
Volume
38
Issue
22
Pages
ehv676
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2269729482
Cited by
59
References
9
FWCI
6.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. https://app.cochat.ai/papers/10.1093/eurheartj/ehv676
The paper
Niessner, A., Tamargo, J., Morais, J., Koller, L., Wassmann, S., Husted, S. E., Torp-Pedersen, C., Kjeldsen, K., Lewis, B. S., Drexel, H., Kaski, J. C., Atar, D., Storey, R. F., Lip, G. Y. H., Verheugt, F. W. A., & Agewall, S. (2015). Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.